Related Experiment Video
Updated: Feb 11, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V Pham1, Shengjian Huang2, Hui Zhang2
1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. miwang@mdanderson.org liazhang@mdanderson.org lvpham@mdanderson.org.
Abstract:
Purpose: B-cell lymphoma-2 (BCL-2), an antiapoptotic protein often dysregulated in B-cell lymphomas, promotes cell survival and provides protection from stress. A recent phase I first-in-human study of the BCL-2 inhibitor venetoclax in non-Hodgkin lymphoma showed an overall response rate of 44%. These promising clinical results prompted our examination of the biological effects and mechanism of action underlying venetoclax activity in aggressive B-cell lymphoma, including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).Experimental Design: MCL and DLBCL cell lines, primary patient samples, and in vivo patient-derived xenograft (PDX) models were utilized to examine venetoclax efficacy. Furthermore, the mechanisms underlying venetoclax response and the development of venetoclax resistance were evaluated using proteomics analysis and Western blotting.Results: Potential biomarkers linked to venetoclax activity and targeted combination therapies that can augment venetoclax response were identified. We demonstrate that DLBCL and MCL cell lines, primary patient samples, and PDX mouse models expressing high BCL-2 levels are extremely sensitive to venetoclax treatment. Proteomics studies showed that venetoclax substantially alters the expression levels and phosphorylation status of key proteins involved in cellular processes, including the DNA damage response, cell metabolism, cell growth/survival, and apoptosis. Short- and long-term exposure to venetoclax inhibited PTEN expression, leading to enhanced AKT pathway activation and concomitant susceptibility to PI3K/AKT inhibition. Intrinsic venetoclax-resistant cells possess high AKT activation and are highly sensitive to PI3K/AKT inhibition.Conclusions: These findings demonstrate the on-target effect of venetoclax and offer potential mechanisms to overcome acquired and intrinsic venetoclax resistance through PI3K/AKT inhibition. Clin Cancer Res; 24(16); 3967-80. ©2018 AACR.
Insights
The BCL-2 inhibitor venetoclax shows efficacy in aggressive B-cell lymphomas. Targeting the PI3K/AKT pathway can overcome venetoclax resistance, offering new therapeutic strategies for diffuse large B-cell lymphoma and mantle cell lymphoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- B-cell lymphoma-2 (BCL-2) is an antiapoptotic protein frequently dysregulated in B-cell lymphomas.
- Venetoclax, a BCL-2 inhibitor, has shown promise in early clinical trials for non-Hodgkin lymphoma.
Purpose of the Study:
- To investigate the biological effects and mechanism of action of venetoclax in aggressive B-cell lymphomas, specifically mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).
- To identify biomarkers for venetoclax activity and explore combination therapies to enhance treatment response.
Main Methods:
- Utilized MCL and DLBCL cell lines, primary patient samples, and patient-derived xenograft (PDX) models to assess venetoclax efficacy.
- Employed proteomics analysis and Western blotting to evaluate mechanisms of response and resistance to venetoclax.
Main Results:
- High BCL-2 expression correlated with sensitivity to venetoclax in cell lines, patient samples, and PDX models.
- Venetoclax treatment altered key protein expression and phosphorylation involved in DNA damage response, metabolism, cell growth, and apoptosis.
- Inhibition of PTEN by venetoclax led to increased AKT pathway activation, making cells susceptible to PI3K/AKT inhibition, even in resistant cells.
Conclusions:
- Venetoclax demonstrates on-target effects in aggressive B-cell lymphomas.
- PI3K/AKT inhibition presents a viable strategy to overcome both acquired and intrinsic venetoclax resistance.
Related Concept Videos
Aggression
Strategies of Self-Presentation I: Strategic Self-Presentation
Secondary Motives: Affiliation Motivation and Aggression Motivation
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
Resistance

